Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting
This article was originally published in The Pink Sheet Daily
Executive Summary
Review documents for the targeted oncologic show FDA looking at the product’s approval for first-line renal cell carcinoma in the context of Bayer’s Nexavar approval for the same indication.